U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion battle for Britain's AstraZeneca Plc after having two offers rejected, a chase welcomed by investors in both companies as deal making grips the healthcare industry.Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26, seeking to further discuss a takeover.Buying AstraZeneca would boost Pfizer's pipeline of cancer drugs and create significant cost and tax savings.AstraZeneca shares were up 13 percent on news of the latest approach, which would be the biggest foreign acquisition of a British firm and one of the largest pharmaceutical deals. Pfizer rose 4 percent on the New York Stock Exchange.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN traded higher by 12.96% or $8.9/share to $77.56. In the past year, the shares have traded as low as $46.87 and as high as $70.71. On average, 2448110 shares of AZN exchange hands on a given day and today's volume is recorded at 12379388.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Shares of PFE traded higher by 2.6% or $0.8/share to $31.55. In the past year, the shares have traded as low as $27.12 and as high as $32.96. On average, 28547900 shares of PFE exchange hands on a given day and today's volume is recorded at 40048768.
Source
